Rigel Pharmaceuticals Inc (Nasdaq:RIGL), a commercial stage biotechnology company focused on haematologic disorders and cancer, announced on Thursday that the US Food and Drug Administration (FDA) has granted Orphan Drug designation to R289 for the treatment of myelodysplastic syndromes (MDS).
R289 is a potent and selective dual inhibitor of IRAK1 and IRAK4 currently in Phase 1b clinical development for patients with lower-risk MDS who are relapsed or refractory to prior therapies.
Orphan Drug designation provides Rigel with potential benefits including tax credits, reduced FDA fees and seven years of market exclusivity following potential drug approval. This designation follows the previously granted Fast Track designation for R289 in this patient population.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval